世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Peptide And Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Product (Peptides, Oligonucleotides) By Service (Contract Development, Contract Manufacturing), By End Use, By Region, And Segment Forecasts, 2025 - 2033
Peptide and Oligonucleotide CDMO Market Summary The global peptide and oligonucleotide CDMO market size was valued at USD 2.80 billion in 2024 and is projected to reach USD 8.14 billion by 2033... もっと見る
英語原文をAIを使って翻訳しています。
SummaryPeptide and Oligonucleotide CDMO Market SummaryThe global peptide and oligonucleotide CDMO market size was valued at USD 2.80 billion in 2024 and is projected to reach USD 8.14 billion by 2033, growing at a CAGR of 12.75% from 2025 to 2033. The market is driven due to increasing demand for complex and targeted therapeutics, growing investment in biologics and nucleic acid-based drug development, rising outsourcing trends among pharmaceutical and biopharmaceutical companies, and advancements in synthesis and delivery technologies for peptides and oligonucleotides. In addition, oligonucleotides and peptides have shown potential in treating a wide range of ailments, including metabolic disorders, cancer, and genetic diseases. Innovations in peptide synthesis, synthetic chemistry, and oligonucleotide manufacturing have made it easier to produce and design complex molecules. This has substantially increased the applications of peptides and oligonucleotides in therapeutic usage and thus boosted the demand for contract development and manufacturing organizations (CDMOs) with specialized proficiency in these areas. Furthermore, the rising trend toward personalized medicine has driven the need for customized peptide and oligonucleotide therapies, thereby supporting the demand for CDMOs that are vital in the production and development of these personalized treatment therapies. Moreover, regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have diligently worked on establishing guidelines for the manufacturing and development of oligonucleotides and peptides. Hence, the aforementioned factors are responsible for the lucrative growth of the market. Global Peptide And Oligonucleotide CDMO Market Report Segmentation This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global peptide and oligonucleotide CDMO market report based on product, service, end use, and region. • Product Outlook (Revenue, USD Million, 2021 - 2033) • Peptides • Oligonucleotides • Service Outlook (Revenue, USD Million, 2021 - 2033) • Contract Development • Contract Manufacturing • End Use Outlook (Revenue, USD Million, 2021 - 2033) • Pharmaceutical Companies • Biopharmaceutical Companies • Others • Regional Outlook (Revenue, USD Million, 2021 - 2033) • North America o U.S. o Canada o Mexico • Europe o UK o Germany o France o Italy o Spain o Denmark o Norway o Sweden • Asia Pacific o Japan o China o India o Australia o South Korea o Thailand • Latin America o Brazil o Argentina • Middle East and Africa (MEA) o South Africa o Saudi Arabia o UAE o Kuwait o Oman o Qatar Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation and Scope 1.2. Market Definitions 1.3. Research Methodology 1.4. Information Procurement 1.4.1. Purchased database 1.4.2. GVR’s internal database 1.4.3. Secondary sources 1.4.4. Primary research 1.5. Information or Data Analysis 1.5.1. Data analysis models 1.6. Market Formulation & Validation 1.7. Model Details 1.7.1. Commodity flow analysis (Model 1) 1.7.2. Value chain based analysis (Model 2) 1.7.3. Multivariate Analysis (Model 3) 1.8. List of Secondary Sources 1.9. List of Primary Sources 1.10. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.3. Competitive Landscape Insights Chapter 3. Peptide and Oligonucleotide CDMO Market: Variables, Trends, & Scope 3.1. Market Lineage Outlook 3.1.1. Parent Market Outlook 3.1.2. Ancillary Market Outlook 3.2. Peptide and Oligonucleotide CDMO Market Dynamics 3.2.1. Market Driver Impact Analysis 3.2.2. Market Restraint Analysis 3.2.3. Market Opportunities 3.3. Technological Landscape 3.4. Pricing Model Analysis 3.5. Tariff Impact Analysis 3.6. Supply Chain Analysis 3.7. Market Analysis Tools 3.7.1. Porter’s Five Forces Analysis 3.7.2. PESTEL by SWOT Analysis Chapter 4. Peptide and Oligonucleotide CDMO Market: Product Estimates & Trend Analysis 4.1. Segment Dashboard 4.2. Global Peptide and Oligonucleotide CDMO Market Product Movement Analysis 4.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million) 4.4. Peptides 4.4.1. Peptides Market Estimates and Forecasts, 2021 - 2033 (USD million) 4.5. Oligonucleotides 4.5.1. Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million) Chapter 5. Peptide and Oligonucleotide CDMO Market: Service Estimates & Trend Analysis 5.1. Segment Dashboard 5.2. Global Peptide and Oligonucleotide CDMO Market Service Movement Analysis 5.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million) 5.4. Contract Development 5.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million) 5.5. Contract Manufacturing 5.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million) Chapter 6. Peptide and Oligonucleotide CDMO Market: End Use Estimates & Trend Analysis 6.1. Segment Dashboard 6.2. Global Peptide and Oligonucleotide CDMO Market End Use Movement Analysis 6.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million) 6.4. Pharmaceutical Companies 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million) 6.5. Biopharmaceutical Companies 6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million) 6.6. Others 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million) Chapter 7. Peptide and Oligonucleotide CDMO Market: Regional Estimates & Trend Analysis by Product, Service, End Use 7.1. Regional Market Dashboard 7.2. Global Regional Market Snapshot 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033: 7.4. North America 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4.2. U.S. 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Regulatory Framework 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4.3. Canada 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Regulatory Framework 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4.4. Mexico 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Regulatory Framework 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5. Europe 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.2. UK 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Regulatory Framework 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.3. Germany 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Regulatory Framework 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.4. France 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Regulatory Framework 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.5. Italy 7.5.5.1. Key Country Dynamics 7.5.5.2. Competitive Scenario 7.5.5.3. Regulatory Framework 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.6. Spain 7.5.6.1. Key Country Dynamics 7.5.6.2. Competitive Scenario 7.5.6.3. Regulatory Framework 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.7. Denmark 7.5.7.1. Key Country Dynamics 7.5.7.2. Competitive Scenario 7.5.7.3. Regulatory Framework 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.8. Sweden 7.5.8.1. Key Country Dynamics 7.5.8.2. Competitive Scenario 7.5.8.3. Regulatory Framework 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.9. Norway 7.5.9.1. Key Country Dynamics 7.5.9.2. Competitive Scenario 7.5.9.3. Regulatory Framework 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.6. Asia Pacific 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.6.2. Japan 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Regulatory Framework 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.6.3. China 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Regulatory Framework 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.6.4. India 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Regulatory Framework 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.6.5. Australia 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Regulatory Framework 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.6.6. South Korea 7.6.6.1. Key Country Dynamics 7.6.6.2. Competitive Scenario 7.6.6.3. Regulatory Framework 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.6.7. Thailand 7.6.7.1. Key Country Dynamics 7.6.7.2. Competitive Scenario 7.6.7.3. Regulatory Framework 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.7. Latin America 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.7.2. Brazil 7.7.2.1. Key Country Dynamics 7.7.2.2. Competitive Scenario 7.7.2.3. Regulatory Framework 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.7.3. Argentina 7.7.3.1. Key Country Dynamics 7.7.3.2. Competitive Scenario 7.7.3.3. Regulatory Framework 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.8. MEA 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.8.2. South Africa 7.8.2.1. Key Country Dynamics 7.8.2.2. Competitive Scenario 7.8.2.3. Regulatory Framework 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.8.3. Saudi Arabia 7.8.3.1. Key Country Dynamics 7.8.3.2. Competitive Scenario 7.8.3.3. Regulatory Framework 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.8.4. UAE 7.8.4.1. Key Country Dynamics 7.8.4.2. Competitive Scenario 7.8.4.3. Regulatory Framework 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.8.5. Kuwait 7.8.5.1. Key Country Dynamics 7.8.5.2. Competitive Scenario 7.8.5.3. Regulatory Framework 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.8.6. Oman 7.8.6.1. Key Country Dynamics 7.8.6.2. Competitive Scenario 7.8.6.3. Regulatory Framework 7.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.8.7. Qatar 7.8.7.1. Key Country Dynamics 7.8.7.2. Competitive Scenario 7.8.7.3. Regulatory Framework 7.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million) Chapter 8. Competitive Landscape 8.1. Company Categorization 8.1.1. Market Leaders 8.1.2. Emerging Players 8.2. Peptide and Oligonucleotide CDMO Market Share Analysis, 2024 8.3. Company Profiles 8.3.1. PolyPeptide Group 8.3.1.1. Company Overview 8.3.1.2. Financial Performance 8.3.1.3. Product/Service Benchmarking 8.3.1.4. Strategic Initiatives 8.3.2. STA Pharmaceutical Co. Ltd. 8.3.2.1. Company Overview 8.3.2.2. Financial Performance 8.3.2.3. Product/Service Benchmarking 8.3.2.4. Strategic Initiatives 8.3.3. Bachem 8.3.3.1. Company Overview 8.3.3.2. Financial Performance 8.3.3.3. Product/Service Benchmarking 8.3.3.4. Strategic Initiatives 8.3.4. Creative Peptides 8.3.4.1. Company Overview 8.3.4.2. Financial Performance 8.3.4.3. Product/Service Benchmarking 8.3.4.4. Strategic Initiatives 8.3.5. Aurigene Pharmaceutical Services Ltd. 8.3.5.1. Company Overview 8.3.5.2. Financial Performance 8.3.5.3. Product/Service Benchmarking 8.3.5.4. Strategic Initiatives 8.3.6. Merck KGaA 8.3.6.1. Company Overview 8.3.6.2. Financial Performance 8.3.6.3. Product/Service Benchmarking 8.3.6.4. Strategic Initiatives 8.3.7. EUROAPI 8.3.7.1. Company Overview 8.3.7.2. Financial Performance 8.3.7.3. Product/Service Benchmarking 8.3.7.4. Strategic Initiatives 8.3.8. Curia Global, Inc. 8.3.8.1. Company Overview 8.3.8.2. Financial Performance 8.3.8.3. Product/Service Benchmarking 8.3.8.4. Strategic Initiatives 8.3.9. CordenPharma 8.3.9.1. Company Overview 8.3.9.2. Financial Performance 8.3.9.3. Product/Service Benchmarking 8.3.9.4. Strategic Initiatives 8.3.10. Sylentis, S.A. 8.3.10.1. Company Overview 8.3.10.2. Financial Performance 8.3.10.3. Product/Service Benchmarking 8.3.10.4. Strategic Initiatives List of Tables/GraphsList of TablesTable 1 List of Secondary Sources Table 2 List of Abbreviation Table 3 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 4 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 5 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 6 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million) Table 7 U.S. Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 8 U.S. Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 9 U.S. Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 10 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 11 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 12 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 13 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 14 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 15 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 16 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 17 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 18 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 19 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million) Table 20 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 21 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 22 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 23 Germany Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 24 Germany Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 25 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 26 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 27 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 28 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 29 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 30 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 31 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 32 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 33 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 34 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 35 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 36 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 37 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 38 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 39 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 40 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 41 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 42 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 43 Asia Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 44 Asia Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 45 Asia Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 46 Asia Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million) Table 47 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 48 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 49 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 50 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 51 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 52 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 53 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 54 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 55 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 56 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 57 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 58 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 59 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 60 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 61 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 62 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 63 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 64 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 65 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 66 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 67 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 68 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million) Table 69 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 70 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 71 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 72 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 73 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 74 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 75 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 76 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 77 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 78 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million) Table 79 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 80 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 81 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 82 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 83 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 84 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 85 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 86 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 87 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 88 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 89 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 90 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 91 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 92 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 93 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million) Table 94 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million) Table 95 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million) Table 96 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)List of Figures Fig. 1 Peptide and Oligonucleotide CDMO Market Segmentation Fig. 2 Market Research Process Fig. 3 Information Procurement Fig. 4 Primary Research Pattern Fig. 5 Market Research Approaches Fig. 6 Market Formulation & Validation Fig. 7 Commodity Flow Analysis Fig. 8 Value-Chain-Based Sizing & Forecasting Fig. 9 QFD Model Sizing & Forecasting Fig. 10 Bottom-up Approach Fig. 11 Market Snapshot Fig. 12 Segment Snapshot Fig. 13 Segment Snapshot Fig. 14 Segment Snapshot Fig. 15 Competitive Landscape Snapshot Fig. 16 Parent Market Outlook, 2024 (USD Million) Fig. 17 Ancillary Market Outlook, 2024 (USD Million) Fig. 18 Peptide and Oligonucleotide CDMO Market Dynamics Fig. 19 Porter’s Five Forces Analysis Fig. 20 PESTEL by SWOT Analysis Fig. 21 Peptide and Oligonucleotide CDMO Market Product Outlook: Segment Dashboard Fig. 22 Peptide and Oligonucleotide CDMO Market, by Product Segment: Market Share, 2025 & 2033 Fig. 23 Peptides Market Estimates and forecasts, 2021 - 2033 (USD Million) Fig. 24 Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 25 Peptide and Oligonucleotide CDMO Market Service outlook: Segment dashboard Fig. 26 Peptide and Oligonucleotide CDMO Market, by Service Segment: Market Share, 2025 & 2033 Fig. 27 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 28 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 29 Peptide and Oligonucleotide CDMO Market End Use Outlook: Segment Dashboard Fig. 30 Peptide and Oligonucleotide CDMO Market, by End Use Segment: Market Share, 2025 & 2033 Fig. 31 Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 32 Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 33 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 34 Regional marketplace: Key Takeaways Fig. 35 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 36 Key country dynamics Fig. 37 U S Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 38 Key country dynamics Fig. 39 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 40 Key country dynamics Fig. 41 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 42 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 43 Key country dynamics Fig. 44 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 45 Key country dynamics Fig. 46 Germany Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 47 Key country dynamics Fig. 48 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 49 Key country dynamics Fig. 50 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 51 Key country dynamics Fig. 52 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 53 Key country dynamics Fig. 54 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 55 Key country dynamics Fig. 56 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 57 Key country dynamics Fig. 58 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 59 Asia Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 60 Key country dynamics Fig. 61 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 62 Key country dynamics Fig. 63 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 64 Key country dynamics Fig. 65 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 66 Key country dynamics Fig. 67 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 68 Key country dynamics Fig. 69 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 70 Key country dynamics Fig. 71 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 72 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 73 Key country dynamics Fig. 74 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 75 Key country dynamics Fig. 76 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 77 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 78 Key country dynamics Fig. 79 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 80 Key country dynamics Fig. 81 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 82 Key country dynamics Fig. 83 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 84 Key country dynamics Fig. 85 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 86 Key country dynamics Fig. 87 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 88 Key country dynamics Fig. 89 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million) Fig. 90 Market Participant Categorization Fig. 91 Heat Map Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療機器）の最新刊レポート
Grand View Research社の 医療機器分野 での最新刊レポート
本レポートと同じKEY WORD（peptide）の最新刊レポートよくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ（Grand View Research）は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
